CymaBay Therapeutics Stock Price, News & Analysis (NASDAQ:CBAY)

$14.98 +0.11 (+0.74 %)
(As of 02/20/2018 01:05 AM ET)
Previous Close$14.98
Today's Range$14.53 - $15.25
52-Week Range$2.75 - $15.25
Volume1.40 million shs
Average Volume1.12 million shs
Market Capitalization$657.08 million
P/E Ratio-14.83
Dividend YieldN/A
Beta2.04

About CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CBAY
CUSIPN/A
Phone+1-510-2938800

Debt

Debt-to-Equity Ratio0.04%
Current Ratio7.39%
Quick Ratio7.39%

Price-To-Earnings

Trailing P/E Ratio-14.8316831683168
Forward P/E Ratio-17.22
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.17 per share
Price / Book88.12

Profitability

Trailing EPS($1.01)
Net Income$-26,670,000.00
Net MarginsN/A
Return on Equity-115.80%
Return on Assets-70.25%

Miscellaneous

Employees22
Outstanding Shares55,450,000

CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics Inc (NASDAQ:CBAY) posted its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. During the same period in the previous year, the firm earned ($0.25) EPS. View CymaBay Therapeutics' Earnings History.

When will CymaBay Therapeutics make its next earnings announcement?

CymaBay Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 22nd 2018. View Earnings Estimates for CymaBay Therapeutics.

Where is CymaBay Therapeutics' stock going? Where will CymaBay Therapeutics' stock price be in 2018?

11 brokers have issued 12-month price targets for CymaBay Therapeutics' stock. Their predictions range from $12.00 to $27.00. On average, they expect CymaBay Therapeutics' stock price to reach $16.56 in the next twelve months. View Analyst Ratings for CymaBay Therapeutics.

What are Wall Street analysts saying about CymaBay Therapeutics stock?

Here are some recent quotes from research analysts about CymaBay Therapeutics stock:

  • 1. According to Zacks Investment Research, "CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. " (1/26/2018)
  • 2. Cantor Fitzgerald analysts commented, "Expanded and extended Phase 2 trial could sync with EASL and AASLD. On today’s 3Q17 results conference call, management noted that all patients in the initial 12-week period of the low-dose study have entered the extension phase. At a minimum, we view the commentary as good news from a safety and tolerability standpoint and we assume it unlikely that patients would remain on drug even if safe and tolerable if there is deemed to be no clinical benefit. Management noted that the data set will mature" with time and that 6-month data could become available in 1H18 and 12-month data in 2H18. We note that EASL is scheduled for April 11-15 in Paris and AASLD is scheduled for November 9-13, 2018 in San Francisco." (11/8/2017)
  • 3. HC Wainwright analysts commented, " Recall, on December 7, CymaBay initiated an open-label, dose-ranging Phase 2 study (NCT02955602) of seladelpar (MBX-8025) in about 36 patients with primary biliary cholangitis (PBC) who are not adequately responding to, or are intolerant of, ursodeoxycholic acid (UCDA). Notably, the study sites are located in U.S., Canada, Germany and the U.K. Per protocol, patients are randomized to either 5 mg or 10 mg for 8 weeks. Based on review of the safety and efficacy of the 8 week data, new patients are then enrolled to receive 25 mg of seladelpar for 8 weeks. We also point out that the study incorporates an extension phase where patients are able to continue treatment for a total of 26 weeks, thus allowing for dose adjustments. In this trial, the primary endpoint is the reduction of alkaline phosphate (ALP) from baseline. Preliminary results from the first two cohorts (5 mg and 10 mg) are expected in early 3Q17 (likely July), with data readout of the third cohort (25 mg) anticipated by year end. Ahead of this important, near-term value inflection, we affirm our Buy rating on CBAY shares and raise our price target to $7." (3/27/2017)
  • 4. Piper Jaffray Companies analysts commented, "CymaBay ended 2016 with cash of $17 million, and subsequently CymaBay received $5 million upfront from Kowa in January and raised net proceeds of $9.2 million in February bringing pro forma cash to ~$31 million. CymaBay will report Phase II data on 5mg and 10mg seladelpar in primary biliary cholangitis (PBC) in 3Q:17 followed by 25mg seladelpar data in 4Q:17. We will look for ALP reduction with enhanced liver safety following 3 transaminase elevations at higher doses in the prior study. Encouraging preclinical data for seladelpar in NASH could lead to a pre-IND meeting with the FDA in 2Q:17. CymaBay has partnered Phase III-ready arhalophenate with Kowa in the U.S., and could partner in Europe. We reiterate our Overweight rating and are increasing our price target to $6.50 from $5 by adding value for seladelpar in NASH." (3/24/2017)

Who are some of CymaBay Therapeutics' key competitors?

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the folowing people:

  • Robert James Wills Ph.D., Chairman of the Board (Age 62)
  • Sujal Shah, President, Chief Executive Officer (Age 42)
  • Charles A McWherter Ph.D, Senior Vice President, Chief Scientific Officer (Age 62)
  • Daniel Menold, Vice President - Finance, Principal Financial Officer, Principal Accounting Officer (Age 47)
  • Kirk Rosemark, Vice President - Regulatory Affairs and Quality Assurance (Age 44)
  • Paul T. Quinlan, General Counsel, Corporate Secretary (Age 53)
  • Pol F. Boudes M.D., Chief Medical Officer (Age 58)
  • Robert Booth Ph.D., Director
  • Caroline Loewy, Director
  • Evan A. Stein M.D. Ph.D., Director

Who owns CymaBay Therapeutics stock?

CymaBay Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (4.84%), Redmile Group LLC (3.61%), Franklin Resources Inc. (2.61%), Farallon Capital Management LLC (1.98%), Citadel Advisors LLC (1.25%) and BlackRock Inc. (1.25%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer, Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Institutional Ownership Trends for CymaBay Therapeutics.

Who sold CymaBay Therapeutics stock? Who is selling CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Deutsche Bank AG, Franklin Resources Inc., EAM Investors LLC, Bank of New York Mellon Corp and Ellington Management Group LLC. Company insiders that have sold CymaBay Therapeutics company stock in the last year include Carl Goldfischer and Kurt Von Emster. View Insider Buying and Selling for CymaBay Therapeutics.

Who bought CymaBay Therapeutics stock? Who is buying CymaBay Therapeutics stock?

CymaBay Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, UBS Asset Management Americas Inc., Nexthera Capital LP, Ardsley Advisory Partners, Redmile Group LLC, Perceptive Advisors LLC, Sphera Funds Management LTD. and Candriam Luxembourg S.C.A.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Charles Mcwherter, Kurt Von Emster, Robert James Wills and Sujal Shah. View Insider Buying and Selling for CymaBay Therapeutics.

How do I buy CymaBay Therapeutics stock?

Shares of CymaBay Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CymaBay Therapeutics stock can currently be purchased for approximately $14.98.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $657.08 million. The biopharmaceutical company earns $-26,670,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. CymaBay Therapeutics employs 22 workers across the globe.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7999 Gateway Blvd Ste 130, NEWARK, CA 94560-1188, United States. The biopharmaceutical company can be reached via phone at +1-510-2938800 or via email at [email protected]


MarketBeat Community Rating for CymaBay Therapeutics (CBAY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  343
MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CymaBay Therapeutics (NASDAQ:CBAY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.56$14.50$14.00$13.71
Price Target Upside: 35.15% upside50.57% upside68.07% upside116.66% upside

CymaBay Therapeutics (NASDAQ:CBAY) Consensus Price Target History

Price Target History for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ:CBAY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018Evercore ISIInitiated CoverageOutperform -> OutperformHighView Rating Details
1/25/2018Roth CapitalReiterated RatingBuy -> Buy$27.00HighView Rating Details
1/24/2018HC WainwrightReiterated RatingBuy -> Buy$12.00 -> $18.00HighView Rating Details
1/10/2018OppenheimerSet Price TargetBuy$15.00MediumView Rating Details
11/28/2017Leerink SwannReiterated RatingBuy$16.00HighView Rating Details
11/8/2017Cantor FitzgeraldReiterated RatingBuy$16.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$12.00N/AView Rating Details
8/18/2017SunTrust BanksInitiated CoverageBuy -> Buy$15.00HighView Rating Details
8/11/2017Ifs SecuritiesDowngradeStrong-Buy -> OutperformHighView Rating Details
7/20/2017CIBCReiterated RatingOutperform -> Outperform$8.00 -> $15.00MediumView Rating Details
7/20/2017CitigroupReiterated RatingOutperform$8.00 -> $15.00MediumView Rating Details
(Data available from 2/20/2016 forward)

Earnings

CymaBay Therapeutics (NASDAQ:CBAY) Earnings History and Estimates Chart

Earnings by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ CBAY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018($0.13)N/AView Earnings Details
11/8/2017Q3 2017($0.19)($0.21)$9.50 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.25)($0.31)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.27)($0.20)$4.79 millionViewN/AView Earnings Details
3/23/2017Q4 2016($0.28)($0.30)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.31)($0.25)ViewListenView Earnings Details
8/9/2016Q2($0.32)($0.30)ViewN/AView Earnings Details
5/11/2016Q1($0.28)($0.29)ViewListenView Earnings Details
3/29/2016Q4($0.35)($0.26)ViewListenView Earnings Details
11/12/2015Q315($0.33)($0.27)ViewListenView Earnings Details
8/10/2015Q215($0.42)($0.09)ViewListenView Earnings Details
5/7/2015Q1 2015($0.43)($0.44)ViewN/AView Earnings Details
3/18/2015Q414($0.46)($0.87)ViewN/AView Earnings Details
11/12/2014Q314($0.48)($0.44)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CymaBay Therapeutics (NASDAQ:CBAY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.28)($0.19)($0.23)
Q2 20183($0.24)$0.48$0.01
Q3 20183($0.26)$0.35($0.04)
Q4 20183($0.28)($0.24)($0.26)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for CymaBay Therapeutics (NASDAQ:CBAY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CymaBay Therapeutics (NASDAQ CBAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.10%
Institutional Ownership Percentage: 60.12%
Insider Trades by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)
Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics (NASDAQ CBAY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2018Kurt Von EmsterDirectorBuy153,846$6.50$999,999.0090,000View SEC Filing  
2/14/2018Kurt Von EmsterDirectorSell218,057$15.89$3,464,925.73View SEC Filing  
2/7/2018Kurt Von EmsterDirectorSell40,763$12.35$503,423.0590,000View SEC Filing  
2/5/2018Kurt Von EmsterDirectorSell18,831$12.14$228,608.34View SEC Filing  
2/2/2018Kurt Von EmsterDirectorSell90,098$12.15$1,094,690.70View SEC Filing  
1/31/2018Kurt Von EmsterDirectorSell97,639$12.22$1,193,148.5890,000View SEC Filing  
1/25/2018Kurt Von EmsterDirectorSell39,438$12.18$480,354.8490,000View SEC Filing  
1/22/2018Kurt Von EmsterDirectorSell138,253$10.40$1,437,831.2090,000View SEC Filing  
1/19/2018Kurt Von EmsterDirectorSell144,216$10.25$1,478,214.0090,000View SEC Filing  
1/5/2018Kurt Von EmsterDirectorSell4,300$10.21$43,903.0090,000View SEC Filing  
12/22/2017Kurt Von EmsterDirectorSell173,192$9.41$1,629,736.7290,000View SEC Filing  
11/10/2017Kurt Von EmsterDirectorSell50,048$9.26$463,444.4890,000View SEC Filing  
11/2/2017Carl GoldfischerDirectorSell18,000$8.66$155,880.009,000View SEC Filing  
11/2/2017Charles McwherterSVPBuy5,000$8.67$43,350.0010,300View SEC Filing  
10/31/2017Kurt Von EmsterDirectorSell59,209$9.27$548,867.4390,000View SEC Filing  
10/3/2017Kurt Von EmsterDirectorSell108,876$7.85$854,676.60View SEC Filing  
9/29/2017Kurt Von EmsterDirectorSell211,124$8.09$1,707,993.16View SEC Filing  
8/1/2017Robert James WillsDirectorBuy5,000$6.84$34,200.0025,200View SEC Filing  
7/20/2017Charles McwherterSVPBuy5,000$7.43$37,150.005,100View SEC Filing  
7/20/2017Sujal ShahInsiderBuy10,000$7.34$73,400.0075,891View SEC Filing  
9/6/2016Robert James WillsDirectorBuy25,000$2.43$60,750.0025,000View SEC Filing  
4/15/2016Charles McwherterVPBuy3,000$1.68$5,040.005,000View SEC Filing  
4/5/2016Sujal ShahCFOBuy55,000$1.39$76,450.0042,000View SEC Filing  
4/4/2016Sujal ShahCFOBuy22,000$1.39$30,580.0042,000View SEC Filing  
9/11/2015Carl GoldfischerDirectorSell46,729$2.74$128,037.46View SEC Filing  
8/14/2015Emster Kurt VonDirectorBuy90,000$2.69$242,100.00View SEC Filing  
7/20/2015Emster Kurt VonDirectorBuy1,600,000$2.81$4,496,000.00View SEC Filing  
5/18/2015Sujal ShahCFOBuy10,000$3.40$34,000.00View SEC Filing  
5/18/2015Wart Harold VanCEOBuy7,500$3.34$25,050.00View SEC Filing  
5/15/2015Charles McwherterVPBuy2,000$3.16$6,320.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CymaBay Therapeutics (NASDAQ CBAY) News Headlines

Source:
DateHeadline
Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 218,057 Shares of StockInsider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 218,057 Shares of Stock
www.americanbankingnews.com - February 15 at 9:10 PM
4 charts to watch as tech stocks rebound - MarketWatch - MarketWatch4 charts to watch as tech stocks rebound - MarketWatch - MarketWatch
www.marketwatch.com - February 15 at 6:00 AM
4 charts to watch as tech stocks rebound4 charts to watch as tech stocks rebound
finance.yahoo.com - February 14 at 3:22 PM
Evercore ISI Initiates Coverage on CymaBay Therapeutics (CBAY)Evercore ISI Initiates Coverage on CymaBay Therapeutics (CBAY)
www.americanbankingnews.com - February 13 at 11:54 PM
CymaBay Therapeutics Inc (CBAY) Director Purchases $999,999.00 in StockCymaBay Therapeutics Inc (CBAY) Director Purchases $999,999.00 in Stock
www.americanbankingnews.com - February 12 at 6:32 PM
Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 40,763 Shares of StockInsider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 40,763 Shares of Stock
www.americanbankingnews.com - February 9 at 6:20 PM
Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics - PR Newswire (press release)Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics - PR Newswire (press release)
www.prnewswire.com - February 9 at 3:26 PM
Kurt Von Emster Sells 18,831 Shares of CymaBay Therapeutics Inc (CBAY) StockKurt Von Emster Sells 18,831 Shares of CymaBay Therapeutics Inc (CBAY) Stock
www.americanbankingnews.com - February 8 at 12:46 AM
CymaBay Therapeutics to Participate in Investor Conferences in FebruaryCymaBay Therapeutics to Participate in Investor Conferences in February
finance.yahoo.com - February 6 at 3:20 PM
Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 90,098 Shares of StockInsider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 90,098 Shares of Stock
www.americanbankingnews.com - February 5 at 6:26 PM
CymaBay Therapeutics Inc (CBAY) Given Average Recommendation of "Buy" by AnalystsCymaBay Therapeutics Inc (CBAY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 5 at 1:46 AM
CymaBay Therapeutics Inc (CBAY) Director Sells $1,193,148.58 in StockCymaBay Therapeutics Inc (CBAY) Director Sells $1,193,148.58 in Stock
www.americanbankingnews.com - February 1 at 6:10 PM
CymaBay Therapeutics (CBAY) Commences Common Stock Offering - StreetInsider.comCymaBay Therapeutics (CBAY) Commences Common Stock Offering - StreetInsider.com
www.streetinsider.com - January 30 at 3:18 PM
CymaBay Therapeutics (CBAY) Commences Common Stock OfferingCymaBay Therapeutics (CBAY) Commences Common Stock Offering
www.streetinsider.com - January 30 at 5:46 AM
CymaBay Announces Proposed Public Offering of Common StockCymaBay Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 30 at 5:46 AM
CymaBay Therapeutics (CBAY) Buy Rating Reaffirmed at HC WainwrightCymaBay Therapeutics' (CBAY) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - January 28 at 5:34 PM
CymaBay Therapeutics (CBAY) Upgraded at BidaskClubCymaBay Therapeutics (CBAY) Upgraded at BidaskClub
www.americanbankingnews.com - January 27 at 3:58 PM
CymaBay Therapeutics Inc (CBAY) Director Sells $480,354.84 in StockCymaBay Therapeutics Inc (CBAY) Director Sells $480,354.84 in Stock
www.americanbankingnews.com - January 26 at 9:28 PM
CymaBay Therapeutics (CBAY) Upgraded to "Hold" at Zacks Investment ResearchCymaBay Therapeutics (CBAY) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 26 at 7:04 PM
Roth Capital Initiates Coverage on CymaBay Therapeutics (CBAY)Roth Capital Initiates Coverage on CymaBay Therapeutics (CBAY)
www.americanbankingnews.com - January 25 at 11:12 AM
Kurt Von Emster Sells 138,253 Shares of CymaBay Therapeutics Inc (CBAY) StockKurt Von Emster Sells 138,253 Shares of CymaBay Therapeutics Inc (CBAY) Stock
www.americanbankingnews.com - January 24 at 6:28 PM
Kurt Von Emster Sells 144,216 Shares of CymaBay Therapeutics Inc (CBAY) StockKurt Von Emster Sells 144,216 Shares of CymaBay Therapeutics Inc (CBAY) Stock
www.americanbankingnews.com - January 22 at 6:34 PM
Zacks: Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 MillionZacks: Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million
www.americanbankingnews.com - January 22 at 4:50 AM
Zacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.12 Per ShareZacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Earnings of -$0.12 Per Share
www.americanbankingnews.com - January 20 at 5:14 PM
CymaBay Therapeutics (CBAY) Stock Rating Lowered by Zacks Investment ResearchCymaBay Therapeutics (CBAY) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 16 at 7:56 PM
CymaBay Therapeutics Inc (CBAY) Receives Consensus Recommendation of "Buy" from BrokeragesCymaBay Therapeutics Inc (CBAY) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 11 at 1:58 AM
Kurt Von Emster Sells 4,300 Shares of CymaBay Therapeutics Inc (CBAY) StockKurt Von Emster Sells 4,300 Shares of CymaBay Therapeutics Inc (CBAY) Stock
www.americanbankingnews.com - January 9 at 7:16 PM
CymaBay Therapeutics (CBAY) Commences Enrollment in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary CholangitisCymaBay Therapeutics (CBAY) Commences Enrollment in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis
www.streetinsider.com - January 8 at 5:35 PM
Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary CholangitisEnrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis
finance.yahoo.com - January 8 at 8:20 AM
CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals AmericaCymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America
finance.yahoo.com - January 8 at 8:20 AM
Zacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 MillionZacks: Analysts Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million
www.americanbankingnews.com - January 5 at 5:02 AM
Zacks: Brokerages Expect CymaBay Therapeutics Inc (CBAY) Will Post Earnings of -$0.12 Per ShareZacks: Brokerages Expect CymaBay Therapeutics Inc (CBAY) Will Post Earnings of -$0.12 Per Share
www.americanbankingnews.com - January 3 at 9:44 PM
CymaBay Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)CymaBay Therapeutics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 6:57 PM
CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceCymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:57 PM
CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 173,192 SharesCymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 173,192 Shares
www.americanbankingnews.com - December 28 at 3:12 PM
CymaBay Therapeutics (CBAY) & Acceleron Pharma (XLRN) Financial ContrastCymaBay Therapeutics (CBAY) & Acceleron Pharma (XLRN) Financial Contrast
www.americanbankingnews.com - December 20 at 7:14 AM
CymaBay Therapeutics Inc (CBAY) Given Average Rating of "Buy" by BrokeragesCymaBay Therapeutics Inc (CBAY) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 17 at 2:22 AM
CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel - GlobeNewswire (press release)CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel - GlobeNewswire (press release)
globenewswire.com - December 5 at 5:26 PM
CymaBay Therapeutics, Inc. – Value Analysis (NASDAQ:CBAY) : December 4, 2017CymaBay Therapeutics, Inc. – Value Analysis (NASDAQ:CBAY) : December 4, 2017
finance.yahoo.com - December 4 at 5:28 PM
CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General CounselCymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel
finance.yahoo.com - December 4 at 9:15 AM
 Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million Brokerages Anticipate CymaBay Therapeutics Inc (CBAY) Will Announce Quarterly Sales of $6.75 Million
www.americanbankingnews.com - December 2 at 10:51 AM
CymaBay Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CBAY-US : December 1, 2017CymaBay Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CBAY-US : December 1, 2017
finance.yahoo.com - December 1 at 4:41 PM
CymaBay Therapeutics Inc to Post FY2019 Earnings of ($1.13) Per Share, Leerink Swann Forecasts (CBAY)CymaBay Therapeutics Inc to Post FY2019 Earnings of ($1.13) Per Share, Leerink Swann Forecasts (CBAY)
www.americanbankingnews.com - November 30 at 7:46 PM
CymaBay Therapeutics (CBAY) Rating Reiterated by Leerink SwannCymaBay Therapeutics (CBAY) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - November 29 at 1:48 PM
CymaBay Therapeutics (CBAY) Given "Buy" Rating at HC WainwrightCymaBay Therapeutics (CBAY) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - November 28 at 2:58 PM
CymaBay Therapeutics Inc. (CBAY) Receives Average Rating of "Buy" from BrokeragesCymaBay Therapeutics Inc. (CBAY) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 22 at 1:34 AM
FY2017 EPS Estimates for CymaBay Therapeutics Inc. (CBAY) Lowered by AnalystFY2017 EPS Estimates for CymaBay Therapeutics Inc. (CBAY) Lowered by Analyst
www.americanbankingnews.com - November 17 at 9:44 PM
SunTrust Banks Comments on CymaBay Therapeutics Inc.s Q1 2018 Earnings (CBAY)SunTrust Banks Comments on CymaBay Therapeutics Inc.'s Q1 2018 Earnings (CBAY)
www.americanbankingnews.com - November 15 at 9:36 AM
Kurt Von Emster Sells 50,048 Shares of CymaBay Therapeutics Inc. (CBAY) StockKurt Von Emster Sells 50,048 Shares of CymaBay Therapeutics Inc. (CBAY) Stock
www.americanbankingnews.com - November 14 at 8:05 PM
CymaBay Therapeutics to Present at Three Investor ConferencesCymaBay Therapeutics to Present at Three Investor Conferences
finance.yahoo.com - November 13 at 11:29 PM

SEC Filings

CymaBay Therapeutics (NASDAQ:CBAY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CymaBay Therapeutics (NASDAQ:CBAY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CymaBay Therapeutics (NASDAQ CBAY) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.